Recent Transactions

20-Feb-24
Pending
$185 million
Australia flag
Target: 

myHomecare Group

Australia flag
Acquiror: 
Australian Unity

Advising Australian Unity on its acquisition of myHomecare Group

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

19-Apr-22
Pending
$107 million
Australia flag
Target: 

Syrah Resources

United States flag
Acquiror: 
U.S. Department of Energy

Advisor to Syrah Resources, an ASX-listed industrial minerals and technology company, on its US$107mm loan from the U.S. Department of Energy under the Advanced Technology Vehicles Manufacturing loan program to fund the initial expansion of its Vidalia active anode material facility in Louisiana, USA

05-Oct-21
$175 million
United Kingdom flag
Target: 

Kao Data Ltd

New Zealand flag
Acquiror: 
Infratil Ltd

Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform

29-Mar-21
Undisclosed
Australia flag
Target: 

Worley’s Capital Projects Advisory business

Australia flag
Acquiror: 
TSA Management

Advised ASX-listed Worley Limited on the sale of its Capital Projects Advisory business, a market leading provider of public infrastructure advisory services in Australia, New Zealand and Southeast Asia, to TSA Management (a portfolio company of Quadrant Private Equity)

19-Dec-18
$NA
Australia flag
Target: 

Starpharma Holdings Limited, patented VivaGel BV® product

Italy, USA flags
Acquiror: 
ITF Pharma, US subsidiary of Italfarmaco S.p.A.

Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company

10-Sep-18
$100 million
Australia flag
Target: 

Montserrat Day Hospital Group

Australia flag
Acquiror: 
Primary Health Care

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

12-Dec-16
$NA
Australia flag
Target: 

Western Sydney Airport

flag not available

Advised the Commonwealth Government of Australia as represented by the Department of Infrastructure and Regional Development in relation to the Western Sydney Airport (Peer Review and other strategic advisory services)

24-Nov-16
$NA
Israel flag
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

09-Aug-16
$NA
Australia flag
Target: 

Bionomics Limited

flag not available

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

28-Jun-16
$NA
Israel flag
Target: 

US rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

28-Jun-16
$652 million
Israel flag
Target: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

21-Jun-16
$586 million
Israel flag
Target: 

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
Israel flag
Target: 

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

16-Jun-16
$40 million
Israel flag
Target: 

US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

11-Jun-16
$350 million
Israel flag
Target: 

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

08-Dec-15
$6+ billion
Australia flag
Target: 

Air Warfare Destroyer Reform Strategy

flag not available

Advised the Commonwealth Government of Australia as represented by the Department of Finance in relation to the Air Warfare Destroyer Reform Strategy

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

19-Dec-14
$NA
United States flag
Target: 

NYK Ports LLC

Australia flag
Acquiror: 
Macquarie Infrastructure Partners

Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

23-Apr-12
$2.0 billion
Australia flag
Target: 

Moorebank Intermodal Terminal

Acted as independent advisor to the Australian Government in a peer review of the proposed intermodal terminal linking Sydney’s major port with Australia’s road and rail system

Pages

show all